ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 28.42% compared to Zoetis's net margin of 21.68%. Zoetis's return on equity of 51.03% beat Eli Lilly and's return on equity of 78.25%.

Zoetis has a consensus price target of $195.04, signalling upside risk potential of 28.7%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Zoetis has higher upside potential than Eli Lilly and, analysts believe Zoetis is more attractive than Eli Lilly and.

Zoetis has a beta of 0.909, which suggesting that the stock is 9.074% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.23%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Zoetis's net income of $631M is lower than Eli Lilly and's net income of $2.8B. Notably, Zoetis's price-to-earnings ratio is 27.21x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.38x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 28.42% compared to Zoetis's net margin of 32.71%. Zoetis's return on equity of 51.03% beat Merck &'s return on equity of 39.02%.

Zoetis has a consensus price target of $195.04, signalling upside risk potential of 28.7%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Zoetis has higher upside potential than Merck &, analysts believe Zoetis is more attractive than Merck &.

Zoetis has a beta of 0.909, which suggesting that the stock is 9.074% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.23%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are smaller than Merck & quarterly revenues of $15.5B. Zoetis's net income of $631M is lower than Merck &'s net income of $5.1B. Notably, Zoetis's price-to-earnings ratio is 27.21x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.38x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 28.42% compared to Zoetis's net margin of -907.48%. Zoetis's return on equity of 51.03% beat Moderna's return on equity of -29.23%.

Zoetis has a consensus price target of $195.04, signalling upside risk potential of 28.7%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Zoetis, analysts believe Moderna is more attractive than Zoetis.

Zoetis has a beta of 0.909, which suggesting that the stock is 9.074% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.23%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are larger than Moderna quarterly revenues of $107M. Zoetis's net income of $631M is higher than Moderna's net income of -$971M. Notably, Zoetis's price-to-earnings ratio is 27.21x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.38x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 28.42% compared to Zoetis's net margin of 21.63%. Zoetis's return on equity of 51.03% beat Pfizer's return on equity of 8.72%.

Zoetis has a consensus price target of $195.04, signalling upside risk potential of 28.7%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Zoetis has higher upside potential than Pfizer, analysts believe Zoetis is more attractive than Pfizer.

Zoetis has a beta of 0.909, which suggesting that the stock is 9.074% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.23%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Zoetis's net income of $631M is lower than Pfizer's net income of $3B. Notably, Zoetis's price-to-earnings ratio is 27.21x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.38x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.